The new indication makes cariprazine the first and only dopamine and serotonin partial agonist to treat the full spectrum of bipolar I symptoms in manic, mixed, and depressive episodes.
Genomic data may improve the selection of more precise models for metastatic breast cancer research.
Top news of the day from across the health care landscape.
Officials with the FDA approved ruxolitinib (Jakafi, Incyte), the first treatment for patients 12 years and older with steroid-refractory acute graft-versus-host disease.
The drug, onasemnogene abeparvovec-xioi (Zolgensma, AveXis), is an adeno-associated virus vector-based gene therapy that targets the cause of SMA, a leading genetic cause of infant mortality.
Top news of the week from Specialty Pharmacy Times.
Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.